Definitive Healthcare (NASDAQ:DH) Cut to “Hold” at Wall Street Zen

Wall Street Zen downgraded shares of Definitive Healthcare (NASDAQ:DH) from a buy rating to a hold rating in a report released on Saturday morning,Wall Street Zen reports.

Other equities analysts have also issued reports about the company. Bank of America reaffirmed an “underperform” rating and set a $0.70 target price on shares of Definitive Healthcare in a research report on Monday, June 29th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $1.00 price target on shares of Definitive Healthcare in a research note on Wednesday, August 12th. Morgan Stanley lowered their price objective on shares of Definitive Healthcare from $2.50 to $1.50 and set an “equal weight” rating on the stock in a report on Tuesday, August 11th. Robert W. Baird set a $1.10 price objective on shares of Definitive Healthcare in a research note on Friday, May 8th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Definitive Healthcare in a research note on Monday, August 31st. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Reduce” and an average target price of $1.47.

Definitive Healthcare Stock Performance

Shares of Definitive Healthcare stock opened at $1.05 on Friday. Definitive Healthcare has a one year low of $0.61 and a one year high of $4.35. The firm has a market capitalization of $112.09 million, a price-to-earnings ratio of -0.66, a PEG ratio of 12.96 and a beta of 1.40. The business has a 50-day simple moving average of $0.77 and a 200 day simple moving average of $0.93. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.86 and a quick ratio of 1.86.

Definitive Healthcare (NASDAQ:DH) last announced its quarterly earnings results on Monday, August 10th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.01. Definitive Healthcare had a positive return on equity of 3.55% and a negative net margin of 72.28%.The business had revenue of $55.20 million for the quarter, compared to analyst estimates of $55.47 million. Definitive Healthcare has set its FY 2026 guidance at 0.180-0.200 EPS and its Q3 2026 guidance at 0.040-0.050 EPS. On average, research analysts anticipate that Definitive Healthcare will post 0.06 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. AQR Capital Management LLC raised its position in Definitive Healthcare by 56.7% in the 1st quarter. AQR Capital Management LLC now owns 590,149 shares of the company’s stock valued at $1,706,000 after buying an additional 213,562 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in Definitive Healthcare by 564.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 8,716,725 shares of the company’s stock worth $25,191,000 after acquiring an additional 7,404,363 shares during the last quarter. Jane Street Group LLC grew its stake in shares of Definitive Healthcare by 166.0% in the 1st quarter. Jane Street Group LLC now owns 105,114 shares of the company’s stock worth $304,000 after acquiring an additional 65,597 shares in the last quarter. Creative Planning grew its stake in shares of Definitive Healthcare by 41.7% in the 2nd quarter. Creative Planning now owns 28,628 shares of the company’s stock worth $112,000 after acquiring an additional 8,428 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in shares of Definitive Healthcare in the second quarter valued at about $4,247,000. Hedge funds and other institutional investors own 98.67% of the company’s stock.

About Definitive Healthcare

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.